N. Mylonakis

1.5k total citations
65 papers, 1.1k citations indexed

About

N. Mylonakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, N. Mylonakis has authored 65 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 24 papers in Surgery. Recurrent topics in N. Mylonakis's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (15 papers) and Cancer Treatment and Pharmacology (14 papers). N. Mylonakis is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (15 papers) and Cancer Treatment and Pharmacology (14 papers). N. Mylonakis collaborates with scholars based in Greece, United States and Brazil. N. Mylonakis's co-authors include P. Kosmidis, George Fountzilas, Christos Kosmas, Melina Pectasides, Nicholas Pavlidis, D. Skarlos, V. Kostopoulou, D. Pectasides, A. Karabelis and Νicolas Tsavaris and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

N. Mylonakis

62 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Mylonakis Greece 19 745 456 294 221 202 65 1.1k
Matthieu Texier France 12 1.3k 1.7× 321 0.7× 266 0.9× 108 0.5× 178 0.9× 31 1.7k
N. Androulakis Greece 20 1.1k 1.5× 681 1.5× 236 0.8× 124 0.6× 182 0.9× 46 1.3k
Magid H. Amer Saudi Arabia 15 495 0.7× 449 1.0× 277 0.9× 180 0.8× 203 1.0× 28 1.2k
Aris Polyzos Greece 19 1.2k 1.6× 607 1.3× 229 0.8× 178 0.8× 267 1.3× 55 1.5k
Jay Wasman United States 20 446 0.6× 245 0.5× 254 0.9× 152 0.7× 295 1.5× 63 1.3k
Alessandra Felici Italy 19 485 0.7× 361 0.8× 293 1.0× 68 0.3× 166 0.8× 49 1.1k
Q. van Hoesel Netherlands 7 590 0.8× 678 1.5× 119 0.4× 57 0.3× 182 0.9× 7 964
F. Shepherd Canada 18 964 1.3× 973 2.1× 315 1.1× 267 1.2× 105 0.5× 48 1.7k
Tracy Proverbs‐Singh United States 7 688 0.9× 268 0.6× 210 0.7× 96 0.4× 116 0.6× 14 1.1k
C. Sessa Switzerland 13 651 0.9× 304 0.7× 267 0.9× 95 0.4× 236 1.2× 24 1.1k

Countries citing papers authored by N. Mylonakis

Since Specialization
Citations

This map shows the geographic impact of N. Mylonakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Mylonakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Mylonakis more than expected).

Fields of papers citing papers by N. Mylonakis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Mylonakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Mylonakis. The network helps show where N. Mylonakis may publish in the future.

Co-authorship network of co-authors of N. Mylonakis

This figure shows the co-authorship network connecting the top 25 collaborators of N. Mylonakis. A scholar is included among the top collaborators of N. Mylonakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Mylonakis. N. Mylonakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kosmas, Christos, George Vorgias, Georgios Tsakonas, et al.. (2011). Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours. British Journal of Cancer. 105(7). 897–902. 2 indexed citations
2.
Kosmas, Christos, N. Mylonakis, Georgios Tsakonas, et al.. (2009). Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. British Journal of Cancer. 101(7). 1059–1065. 24 indexed citations
3.
Kosmas, Christos, Νicolas Tsavaris, Nikolaos Malamos, et al.. (2007). Docetaxel–ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. Investigational New Drugs. 25(5). 463–470.
4.
Briasoulis, Evangelos, George Fountzilas, Aristotelis Bamias, et al.. (2007). Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemotherapy and Pharmacology. 62(2). 277–284. 20 indexed citations
5.
Pectasides, Dimitrios, Petroula Arapantoni-Dadioti, Christos Valavanis, et al.. (2006). HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.. PubMed. 26(1B). 647–53. 58 indexed citations
6.
Kosmas, Christos, Νicolas Tsavaris, Konstantinos Syrigos, et al.. (2006). A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemotherapy and Pharmacology. 59(1). 51–59. 20 indexed citations
7.
Pectasides, D., Melina Pectasides, Dimitrios Farmakis, et al.. (2005). Comparison of docetaxel and docetaxel–irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Annals of Oncology. 16(2). 294–299. 71 indexed citations
8.
Pectasides, D., Melina Pectasides, Dimitrios Farmakis, et al.. (2004). Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study. Annals of Oncology. 15(3). 493–497. 75 indexed citations
9.
Pectasides, D., Melina Pectasides, Dimitrios Farmakis, et al.. (2003). Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Annals of Oncology. 14(4). 537–542. 26 indexed citations
10.
Kosmidis, P., N. Mylonakis, Dimosthenis Skarlos, et al.. (2000). Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial. Annals of Oncology. 11(7). 799–805. 61 indexed citations
11.
Samantas, Epaminontas, Dimosthenis Skarlos, D. Pectasides, et al.. (1999). Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer. Lung Cancer. 23(2). 159–168. 12 indexed citations
12.
13.
Kosmidis, P., N. Mylonakis, George Fountzilas, et al.. (1997). Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study. Annals of Oncology. 8(7). 697–699. 29 indexed citations
14.
Tsavaris, N., et al.. (1995). Efficacy of Ondansetron Treatment with Different Timing Schedules: A Randomized Double–Blind Study. Oncology. 52(4). 315–318. 1 indexed citations
15.
Tsavaris, Νicolas, et al.. (1994). Comparison of Ondansentron (GR 38032F) Versus Ondansentron plus Alprazolam as Antiemetic Prophylaxis During Cisplatin-Containing Chemotherapy. American Journal of Clinical Oncology. 17(6). 516–521. 6 indexed citations
16.
Skarlos, D., E. Samantas, P. Kosmidis, et al.. (1994). Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Annals of Oncology. 5(7). 601–607. 195 indexed citations
17.
Mylonakis, N., et al.. (1993). Treatment of Renal Cell Carcinoma with Escalating Doses of Alpha-lnterferon. Chemotherapy. 39(5). 361–366. 7 indexed citations
18.
Tsavaris, N., et al.. (1992). Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemotherapy and Pharmacology. 30(4). 330–333. 40 indexed citations
19.
Tsavaris, N., et al.. (1990). Comparison of Antiemetic Activity of Chloropromazine and High Doses of Metoclopramide in Cisplatin-Based Chemotherapy. Acta Oncologica. 29(8). 1005–1009. 7 indexed citations
20.
Tsavaris, N., et al.. (1990). Conservative Approach to the Treatment of Chemotherapy‐Induced Extravasation. The Journal of Dermatologic Surgery and Oncology. 16(6). 519–522. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthieu Texier Breakdown of academic impact, for papers by N. Androulakis Breakdown of academic impact, for papers by Magid H. Amer Breakdown of academic impact, for papers by Aris Polyzos Breakdown of academic impact, for papers by Jay Wasman Breakdown of academic impact, for papers by Alessandra Felici Breakdown of academic impact, for papers by Q. van Hoesel Breakdown of academic impact, for papers by F. Shepherd Breakdown of academic impact, for papers by Tracy Proverbs‐Singh Breakdown of academic impact, for papers by C. Sessa
Rankless by CCL
2026